Fritextsökning
Artiklar per år
Innehållstyper
-
Agreement in the EU on eight years of data exclusivity for new medicines
New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agreed upon after prolonged negotiations.
-
US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee
Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretary, his department announced.
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Södertörn District Court in Huddinge, south of Stockholm.
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the markets where these competing treatments are currently available.
-
Venomaid's rapid test aims to find the right snake bite treatment
Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom can help? Danish company Venomaid Diagnostics is working hard to develop solutions to a problem that claims countless lives, especially in tropical countries.
-
Virology professor on the threat from X: ”The next pandemic could be worse“
The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", responds virologist Niklas Arnberg.
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. "We invested for 25 years while everyone else laughed at us. Now everyone wants to join the game," says Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk.
-
Olika bud om distansarbete – ”Vi ber vår personal att komma tillbaka till kontoret”
Hur viktigt är det för life science-bolagen att erbjuda distansarbete? Den frågan väckte debatt och fick många olika svar vid en paneldiskussion om talangrekrytering vid The Future of Swedish and Danish Life Science.
-
Kvinnan bakom Novo Nordisks fetmasuccé: ”Slutade aldrig tro på GLP-1”
Det tog flera år av misslyckanden inom GLP-1 innan Lotte Bjerre Knudsen och hennes kollegor hittade rätt – men då var det en riktig fullträff. "Vi investerade i 25 år, när alla andra skrattade åt oss. Nu vill alla vara med i leken", säger Lotte Bjerre Knudsen, Chief Scientific Advisor på Novo Nordisk.
-
Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm
One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.
-
AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential
AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce environmental impact by 99.9%.
-
Trump in new push to lower drug prices
U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in other wealthy countries — something he claims could reduce prices by 30 to 80 percent.
-
Studie: Eli Lillys Mounjaro överglänser Novo Nordisks Wegovy
På fem olika mål för viktminskning, inklusive minskning av midjeomfång, är Eli Lillys Mounjaro överlägsen Novo Nordisks Wegovy, enligt resultatet från en första jämförande studie.
-
Getinge and Neobiomics received Swecare's export awards
Two companies received awards during Swecare's annual conference.
-
Karriärcoachen: Illusionen om anställningstrygghet är en fälla
Vi måste släppa illusionen av anställningstrygghet. Det anser karriärcoachen Tina Persson som menar att den gör oss bekväma och blind för möjligheterna som finns framför oss.
-
KI-bolag får stöd av Michael J. Fox Foundation
Svenska Umecrine Cognition har fått ett anslag från The Michael J. Fox Foundation för att utvärdera bolagets läkemedelskandidat golexanolon som behandling för Parkinsons sjukdom.
-
Astra Zeneca faces potential multimillion-dollar fines in China
Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following earlier controversies.
-
Merck KGaA acquires American company in €3.0 billion deal
Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.
-
Eli Lilly requests re-examination of Alzheimer's drug recommendation
Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away from us. They followed up by showering us with lawsuits,” he says.
-
Immedica högt på listan över Sveriges bästa arbetsplatser
Stockholmsbaserade Immedica Pharma hamnar tvåa på listan över Sveriges bästa arbetsplatser i kategorin medelstora organisationer. Även andra läkemedelsföretag finns representerade i rankningen.
-
Mikael Kubista tillbaka med ny satsning – efter turbulenta avskedet
Entreprenören och forskaren Mikael Kubista startar ett nytt bolag. Nu är han också fri att kommentera händelseförloppet som ledde till att han förlorade ägandet i sitt livsverk – företaget Tataa Biocenter. ”Inte bara att de tog vårt företag ifrån oss. De följde upp med att överösa oss med stämningar”, säger han.
-
Från apotekare till poddare – Magnus Lejelöv har rösten som verktyg
Magnus Lejelöv har över 20 års erfarenhet från läkemedelssektorn och har intervjuat nära två hundra vårdprofiler i sina poddar. I maj står han på scenen i Lund och ställer sina frågor till talarna när han modererar The Future of Swedish & Danish Life Science 2025.